JD.com Inc. (NASDAQ: JD) is slated to report fourth quarter 2019 earnings results on Monday, March 2, before the opening bell. The consensus estimates are for earnings of $0.06 per share on revenue of $23.7 billion.
The quarterly results are expected to benefit from strength in the retail business and the company’s expansion into lower-tier cities through its social e-commerce platform Jingxi. Last quarter, 75% of Jingxi’s new users were from lower-tier cities.
The company has seen strong growth in revenue, aided by growth in users, over the past quarters and this momentum is expected to continue in the fourth quarter as well. JD.com has been taking efforts to improve its customer experience and this is likely to have brought more users to its platform.
Also read: JD.com Q3 2019 Earnings Conference Call Transcript
The company’s efficient logistics and delivery services are also likely to have fueled the results during the quarter. However, higher costs related to investments are likely to pressure the bottom line. Lower margins are another cause of concern.
Last month, reports emerged about JD.com planning to spin off its logistics arm through an IPO in the second half of the year that would value the company at around $30 billion. It is expected that as a stand-alone entity, JD Logistics would perform better. Separating the capital-intensive business unit might improve the company’s overall cash position and enhance shareholder value. Updates on this area will be worth watching.
In the third quarter of 2019, JD.com beat revenue and earnings estimates. Net revenues increased 28.7% to RMB134.8 billion, or $18.9 billion. Adjusted net income per ADS was RMB2.08 ($0.29).
For the fourth quarter of 2019, net revenues are expected to grow 21-25% to a range between RMB163 billion and RMB168 billion compared to the prior-year period.
Shares of JD.com have gained 17% in the past three months. The stock has a strong Buy rating and an average price target of $47.08.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
